Ondas Inc. Files 424B7 Prospectus Supplement for Securities Offering

TL;DR

**Ondas filed a 424B7, likely prepping for a capital raise.**

AI Summary

Ondas Inc. filed a 424B7 prospectus supplement on March 26, 2026, related to its previously filed registration statement 333-290121. This filing indicates that Ondas, a company based in West Palm Beach, FL, and incorporated in Nevada, is likely offering or reselling securities. This matters to investors because such filings often precede capital raises, which can dilute existing shares or provide funds for growth, impacting the stock's future value.

Why It Matters

This filing signals Ondas Inc. is preparing to issue or resell securities, which could impact share price through dilution or by funding strategic initiatives.

Risk Assessment

Risk Level: medium — The filing of a prospectus supplement for a securities offering introduces uncertainty regarding potential dilution and the use of proceeds, making it a medium risk event.

Analyst Insight

Investors should monitor Ondas Inc. for subsequent filings (like pricing supplements or 8-Ks) that detail the terms of the securities offering, as this will clarify potential dilution and capital infusion.

Key Numbers

• 0001646188 — CIK (Ondas Inc.'s Central Index Key, identifying the company with the SEC)
• 333-290121 — File No. (The registration statement number associated with this prospectus supplement)
• 2026-03-26 — Filing Date (The date the 424B7 prospectus supplement was filed and accepted)
• 390005 — Size (bytes) (The size of the main prospectus supplement document (ea0283197-424b7_ondas.htm))

Key Players & Entities

• Ondas Inc. (company) — the filer of the 424B7 prospectus supplement
• March 26, 2026 (date) — the filing and acceptance date of the 424B7
• 333-290121 (other) — the file number for the related registration statement
• Nevada (other) — state of incorporation for Ondas Inc.
• West Palm Beach, FL (other) — business and mailing address for Ondas Inc.

Forward-Looking Statements

• Ondas Inc. will announce the specific terms of a securities offering, including pricing and share count, within the next 30-60 days. (Ondas Inc.) — medium confidence, target: 2026-05-26

FAQ

Key Financial Figures

• $0.0001 — (“Common Stock”), par value $0.0001 per share (the “Shares”), b
• $117,500,000 — ent, we paid an aggregate amount of (i) $117,500,000 in cash and (ii) issued 4,096,700 share
• $2,500,000 — paid an additional aggregate amount of $2,500,000 in cash and (ii) issued 1,671,899 share
• $10.31 — orted on the Nasdaq Capital Market, was $10.31 per share. Our principal executive offi

Filing Documents

• ea0283197-424b7_ondas.htm (424B7) — 381KB
• ea028319701ex-fee.htm (EX-FILING FEES) — 14KB
• ea028319701_img1.jpg (GRAPHIC) — 3KB
• ea028319701_img2.jpg (GRAPHIC) — 3KB
• ea028319701_img3.jpg (GRAPHIC) — 8KB
• 0001213900-26-034391.txt ( ) — 535KB
• ea028319701ex-fee_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS S-4 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS S-5

USE OF PROCEEDS

USE OF PROCEEDS S-6 DESCRIPTION OF TRANSACTION S-6 SELLING STOCKHOLDERS S-7 PLAN OF DISTRIBUTION S-8 LEGAL MATTERS S-10 EXPERTS S-10 WHERE YOU CAN FIND MORE INFORMATION S-10 INFORMATION INCORPORATED BY REFERENCE S-11 Prospectus Page ABOUT THIS PROSPECTUS ii SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS iii PROSPECTUS SUMMARY 1

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 5 DESCRIPTION OF DEBT SECURITIES 8 DESCRIPTION OF WARRANTS 20 DESCRIPTION OF UNITS 21 GLOBAL SECURITIES 22 PLAN OF DISTRIBUTION 24 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 27 LEGAL MATTERS 27 EXPERTS 27 WHERE YOU CAN FIND ADDITIONAL INFORMATION 27 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 28 This prospectus supplement and accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered hereby in any jurisdiction to or from any person whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. S-i ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus are part of the registration statement on Form S-3ASR (File No. 333-290121) that we filed on September 9, 2025 with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process and consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also supplements and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information, some of which may not apply to this offering. If the information contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus, you should rely on the information set forth in this prospectus supplement. However, if any statement in this prospectus supplement or the accompanying prospectus is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference into this prospectus supplement—the statement in the document having the la

Use Of Proceeds

Use Of Proceeds All proceeds from the sales of the Shares pursuant to this prospectus supplement will go to the selling stockholders. We will not receive any proceeds from the sale of the Shares by the selling stockholders. See the section titled “Use of Proceeds.” Nasdaq Capital Market symbol “ONDS” S-3

RISK FACTORS

RISK FACTORS Investing in our Common Stock involves a high degree of risk. You should carefully consider the risks referenced below and described in the documents incorporated by reference in this prospectus supplement, as well as other information we include or incorporate by reference into this prospectus supplement and the accompanying prospectus before making an investment decision. Our business, financial condition, results of operations and prospects could be materially and adversely affected by the realization of any of these risks. The trading price of our Common Stock could decline due to the materialization of any of these risks, and you may lose all or part of your investment. This prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks referenced below and described in the documents incorporated herein by reference, including (i) our annual report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC and is incorporated herein by reference, as updated by our subsequent annual reports, (ii) our subsequent Quarterly Reports on Form 10-Q, and (iii) other documents we subsequently file with the SEC that are deemed incorporated by reference into this prospectus supplement and the accompanying prospectus. S-4 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and the exhibits attached hereto and thereto contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statement

USE OF PROCEEDS

USE OF PROCEEDS All of the Shares that may be offered by the selling stockholders pursuant to this prospectus supplement will be sold by the selling stockholders for their respective accounts, and we will not receive any proceeds from the sale of the Shares by the selling stockholders. We will pay certain costs, expenses and fees relating to the registration of the Shares for resale by the selling stockholders pursuant to this prospectus supplement. The selling stockholders, however, will pay any fees, discounts, concessions or commissions of any underwriters, broker-dealers or agents, and certain other expenses incurred in connection with the sale or other disposition of the Shares by the selling stockholders. DESCRIPTION OF TRANSACTION On November 3, 2025, we entered into the Purchase Agreement, by and among the Company, Sentry, Sentry’s shareholders listed on Exhibit B thereto, and the Shareholders’ Agent. On the Closing Date, pursuant to the Purchase Agreement, we acquired 100% of the Sentry Shares. On the Closing Date, upon the terms and subject to the conditions set forth in the Purchase Agreement, we paid an aggregate amount of (i) $117,500,000 in cash and (ii) issued 4,096,700 shares of Common Stock. On the Second Payment Date, we (i) paid an additional aggregate amount of $2,500,000 in cash and (ii) issued 1,671,899 shares of Common Stock. On the Third Payment Date, we (i) paid an additional aggregate amount of $2,500,000 in cash and (ii) issued the 1,622,607. On the Fourth Payment Date, we (i) paid an additional aggregate amount of $2,500,000 in cash and (ii) issued the Shares. Pursuant to the Purchase Agreement, the selling stockholders shall be subject to daily trading volume limitations, whereby all such selling stockholders may not sell, in the aggregate, any Common Stock issued to such selling stockholders pursuant to the Purchase Agreement on any Trading Market (as defined in the Purchase Agreement) in any single Trading Day (as d

View Full Filing

View this 424B7 filing on SEC EDGAR